Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24041815 | 0.88 | DHFR (0.40) | DHFRMEN1KMT2ATNK2HSD11B1 | |
| SCHEMBL4381658 | 0.87 | DHFR (0.45) | DHFRMEN1KMT2ATNK2HSD11B1 | |
| SCHEMBL3500438 | 0.86 | TNK2 (0.44) | DHFRMEN1KMT2ATNK2HSD11B1 | |
| SCHEMBL7736919 | 0.85 | MEN1 (0.40) | DHFRMEN1KMT2ATNK2HSD11B1 | |
| SCHEMBL5702480 | 0.84 | DDB1 (0.41) | DHFRMEN1KMT2ATNK2HSD11B1 | |
| SCHEMBL3139148 | 0.84 | DHFR (0.46) | DHFRMEN1KMT2ATNK2HSD11B1 | |
| SCHEMBL5148071 | 0.84 | DHFR (0.44) | DHFRMEN1KMT2ATNK2HSD11B1 | |
| SCHEMBL862862 | 0.84 | MEN1 (0.43) | DHFRMEN1KMT2ATNK2HSD11B1 | |
| SCHEMBL7774639 | 0.84 | DDB1 (0.41) | DHFRMEN1KMT2ATNK2HSD11B1 | |
| SCHEMBL3394710 | 0.83 | MEN1 (0.42) | DHFRMEN1KMT2ATNK2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619212-B1 | BUPRENORPHINE ANALOGS AS OPIOID RECEPTOR AGONISTS AND/OR ANTAGONISTS | PURDUE PHARMA LP (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9221831-B2 | Buprenorphine analogs | PURDUE PHARMA, L.P. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140057931-A1 | BUPRENORPHINE ANALOGS | PURDUE PHARMA L.P. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012038813-A1 | BUPRENORPHINE ANALOGS | PURDUE PHARMA L.P. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057931-A1 | BUPRENORPHINE ANALOGS | OPRL1, OPRD1, OPRK1 | DHFR 2680/4885MEN1 4742/4885KMT2A 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.